UA19765A - Фрагмеhт hуклеїhової кислоти, що кодує людський проаполіпопротеїн а-1 - Google Patents

Фрагмеhт hуклеїhової кислоти, що кодує людський проаполіпопротеїн а-1

Info

Publication number
UA19765A
UA19765A UA4613079A UA4613079A UA19765A UA 19765 A UA19765 A UA 19765A UA 4613079 A UA4613079 A UA 4613079A UA 4613079 A UA4613079 A UA 4613079A UA 19765 A UA19765 A UA 19765A
Authority
UA
Ukraine
Prior art keywords
motiff
nucleic acid
coding human
human proapolipoprotein
proapolipoprotein
Prior art date
Application number
UA4613079A
Other languages
English (en)
Russian (ru)
Inventor
Боллен Алекс
Болен Алекс
Гобер Жан
Вюльферт Ернст
Вюльферт Эрнст
Original Assignee
Юцв С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юцв С.А. filed Critical Юцв С.А.
Publication of UA19765A publication Critical patent/UA19765A/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Винахід відноситься до генетичної інженерії. Він стосується рекомбінантних ДНК, що містять послідовність, кодуючу людський проаполіпопротеїн Α-1. Це поєднання використовується для трансформації штамів-реципієнтів, здатних його продукувати.
UA4613079A 1987-05-28 1988-05-26 Фрагмеhт hуклеїhової кислоти, що кодує людський проаполіпопротеїн а-1 UA19765A (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (1)

Publication Number Publication Date
UA19765A true UA19765A (uk) 1997-12-25

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
UA4613079A UA19765A (uk) 1987-05-28 1988-05-26 Фрагмеhт hуклеїhової кислоти, що кодує людський проаполіпопротеїн а-1

Country Status (33)

Country Link
US (1) US5059528A (uk)
EP (1) EP0293357B1 (uk)
JP (1) JP2634193B2 (uk)
KR (1) KR970000808B1 (uk)
CN (1) CN1031892C (uk)
AT (1) ATE89006T1 (uk)
AU (1) AU615654B2 (uk)
CA (1) CA1323851C (uk)
CY (1) CY1809A (uk)
CZ (1) CZ283648B6 (uk)
DD (1) DD291093A5 (uk)
DE (1) DE3880739T2 (uk)
DK (1) DK175686B1 (uk)
EG (1) EG19101A (uk)
ES (1) ES2054878T3 (uk)
FI (1) FI100056B (uk)
GB (1) GB8712540D0 (uk)
HK (1) HK137794A (uk)
HU (1) HU204562B (uk)
IE (1) IE62422B1 (uk)
IL (1) IL86480A (uk)
LT (1) LT3600B (uk)
LV (1) LV5288A3 (uk)
NO (1) NO179253C (uk)
NZ (1) NZ224808A (uk)
PL (1) PL158064B1 (uk)
PT (1) PT87562B (uk)
RU (1) RU2009198C1 (uk)
SG (1) SG131594G (uk)
SK (1) SK279166B6 (uk)
SU (1) SU1834904A3 (uk)
UA (1) UA19765A (uk)
ZA (1) ZA883824B (uk)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
WO1992009698A1 (en) * 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
DE69115926T2 (de) * 1990-11-30 1996-05-30 Monoclonetics Int Verfahren zur diagnose chronischer niedriger rückenschmerzen und nackenschmerzen
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AU2002232642B2 (en) * 2000-12-12 2007-02-01 Lexicon Pharmaceuticals, Inc. Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
US8153606B2 (en) * 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
SG10201901089TA (en) 2008-11-10 2019-03-28 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
KR101835889B1 (ko) 2009-05-06 2018-03-08 큐알엔에이, 인크. 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료
HUE056773T2 (hu) 2009-06-10 2022-03-28 Arbutus Biopharma Corp Továbbfejlesztett lipid készítmény
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
IL300109A (en) 2010-06-03 2023-03-01 Alnylam Pharmaceuticals Inc Biodegradable lipids for the transfer of active substances
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
RU2017126088A (ru) 2011-02-07 2019-01-31 Серени Терапеутикс Холдинг С.А. Липопротеиновые комплексы и их получение и применения
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
CN111593051A (zh) * 2013-05-01 2020-08-28 Ionis制药公司 组合物和方法
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
EP3137899A2 (en) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Hdl therapy markers
EP3533872A4 (en) * 2016-10-27 2020-09-09 Institute Of Microbiology, Chinese Academy Of Sciences PROCESS FOR MODIFYING AN AMINO ACID ATTENUATOR AND ITS USE IN PRODUCTION
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
US20190048049A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Cargomers
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
AU2021256086A1 (en) 2020-04-16 2022-12-15 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
EP0239631A4 (en) 1985-10-04 1989-01-12 Biotech Res Partners Ltd RECOMBINANT APOLIPOPROTEINS AND METHODS.
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
WO1988003175A1 (en) * 1986-10-29 1988-05-05 Biotechnology Research Partners, Ltd. Apoai-ciii-aiv, apoaii, apob, apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
RU2009198C1 (ru) 1994-03-15
CZ363888A3 (cs) 1998-02-18
FI882456A0 (fi) 1988-05-25
PT87562B (pt) 1992-09-30
EP0293357B1 (fr) 1993-05-05
DE3880739D1 (de) 1993-06-09
DK175686B1 (da) 2005-01-17
LT3600B (en) 1995-12-27
CA1323851C (en) 1993-11-02
AU1672388A (en) 1988-12-01
ES2054878T3 (es) 1994-08-16
NO882341L (no) 1988-11-29
JP2634193B2 (ja) 1997-07-23
JPS6416589A (en) 1989-01-20
NO882341D0 (no) 1988-05-27
KR970000808B1 (en) 1997-01-20
IE62422B1 (en) 1995-02-08
NO179253B (no) 1996-05-28
DD291093A5 (de) 1991-06-20
KR880014110A (ko) 1988-12-22
CZ283648B6 (cs) 1998-05-13
NO179253C (no) 1996-09-04
PL272698A1 (en) 1989-03-06
LV5288A3 (lv) 1993-10-10
CN1031892C (zh) 1996-05-29
AU615654B2 (en) 1991-10-10
SU1834904A3 (ru) 1993-08-15
LTIP828A (en) 1995-02-27
HK137794A (en) 1994-12-16
IE881597L (en) 1988-11-28
DK289688D0 (da) 1988-05-27
DK289688A (da) 1988-11-29
CY1809A (en) 1995-10-20
DE3880739T2 (de) 1993-08-19
SK363888A3 (en) 1998-07-08
EP0293357A1 (fr) 1988-11-30
NZ224808A (en) 1990-01-29
CN88103118A (zh) 1988-12-14
FI882456A (fi) 1988-11-29
US5059528A (en) 1991-10-22
EG19101A (en) 1994-09-29
HUT47153A (en) 1989-01-30
PL158064B1 (pl) 1992-07-31
PT87562A (pt) 1989-05-31
HU204562B (en) 1992-01-28
SK279166B6 (sk) 1998-07-08
FI100056B (fi) 1997-09-15
IL86480A (en) 1992-08-18
ATE89006T1 (de) 1993-05-15
GB8712540D0 (en) 1987-07-01
SG131594G (en) 1995-01-13
ZA883824B (en) 1989-02-22
IL86480A0 (en) 1988-11-15

Similar Documents

Publication Publication Date Title
UA19765A (uk) Фрагмеhт hуклеїhової кислоти, що кодує людський проаполіпопротеїн а-1
IL85701A0 (en) Human manganese superoxide dismutase(hmn-sod),its preparation by genetic engineering,dna sequences coding therefor,vectors containing these dna sequences and host cells which can express them and pharmaceutical compositions containing said enzyme
DE3586189D1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
IL101963A0 (en) Isolated and purified dna sequences coding antigen expressed by tumor cells and recognized by cytotoxic t cells,and uses thereof
HK1153761A1 (en) Cancer antigens based on products of the tumor suppressor gene wt1 wt1
SE8601325L (sv) Sett att producera ett immunglobulinbindande protein samt medel for detta
ES487046A1 (es) Procedimiento de preparacion de proteoglicanos membranarios bacterianos purificados
DK0727483T3 (da) Retrovirus fra HIV-gruppen og dens anvendelse
IL93999A (en) Napthalenecarboxylic acid intermediates for the production of podophyllotoxin and related compounds and their preparation
EP0643719A4 (en) NUCLEIC ACID SEQUENCES ENCODING NUCLEIC ACID SEQUENCES ENCODING THE INTERLEUKIN-9 RECEPTOR, OR COMPLEMENTARY TO THESE SEQUENCES.
AU4569293A (en) Anti-feline immunodeficiency virus (fiv) vaccines
ES2124694T3 (es) Clonacion de la n-metil-hidantoinasa.
DK0674714T3 (da) Rekombinant gastrisk lipase fra hunde og farmaceutiske sammensætninger
ATE107361T1 (de) Gen des hüllproteins des gurkenmosaikvirus.
MY104975A (en) Protease, reverse transcriptase and endonuclease of retrovirus, and method for producing these enzymes.
FR2597707B1 (fr) Renfort des serres contre les surcharges dues aux conditions atmospheriques.
ES2005189A6 (en) Nucleotide sequences from RESA antigen of Plasmodium falciparum